Menu

Blog

Aug 3, 2023

Tackling an aggressive, treatment-resistant lymphoma

Posted by in category: biotech/medical

Anaplastic large cell lymphoma, a form of non-Hodgkin lymphoma, is the most common aggressive lymphoma in children. Chemotherapy and radiation fail to cure about 30% of cases. When tumors are driven by the oncogene ALK—which is the case for the majority of children—kinase inhibitor drugs like crizotinib are very effective in blocking tumor growth. They also lack the serious side effects of chemotherapy.

However, ALK inhibitors also very expensive—about $80,000 a year—and must be taken for a lifetime. As soon as they’re stopped, the lymphoma comes back. Roberto Chiarle, MD, a hematopathologist and researcher at Boston Children’s Hospital, wanted to know why.

“ALK inhibitors can control the lymphoma, but you cannot reach a cure,” he says. “Why do persist for so long?”

Leave a reply